Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Reflux Disease
Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the efficacy and safety of Tegoprazan 50mg, compared to
Lansoprazole 30mg in patients with healed erosive reflux disease confirmed by endoscopy
following oral administration once daily(QD) of 2 weeks or 4 weeks.